Literature DB >> 23801324

The association between race and gender, treatment attitudes, and antidepressant treatment adherence.

Inger Burnett-Zeigler1, H Myra Kim, Claire Chiang, Janet Kavanagh, Kara Zivin, Katherin Rockefeller, Jo Anne Sirey, Helen C Kales.   

Abstract

OBJECTIVES: We examined the associations between treatment attitudes and beliefs with race-gender differences in antidepressant adherence.
METHODS: Subjects (n = 186) were African-American and White subjects aged ≥60 years, diagnosed with clinically significant depression, and had a new outpatient primary care recommendation for antidepressant treatment. Antidepressant adherence was assessed using the Brief Medication Questionnaire. Attitudes and beliefs were assessed using the Patients Attitudes Toward and Ratings of Care for Depression, two items rating perceived medication importance, and a modified version of the Stigma Scale for Receiving Psychological Help.
RESULTS: African-American men and women had significantly greater concerns about antidepressants and significantly less understanding about treatment than White women. African-American men had significantly more negative attitudes toward healthcare providers than African-American and White women. African-American women were more likely than White men and women to endorse a medication other than their antidepressant as most important. Whereas some race-gender differences were found in personal spirituality, no group differences were found in perceived stigma. In a logistic regression model adjusted for key baseline variables, White women were significantly more adherent to antidepressants than African-American women (OR = 3.05, 95% CI = 1.06-8.81). Fewer concerns about antidepressants and indicating the antidepressant as the most important medication were both significantly associated with adherence. After including either of these two variables, the adherence difference between White women and African-American women was no longer significant (OR = 2.56, 95% CI = 0.84-7.80).
CONCLUSIONS: Concerns about antidepressants and the importance of antidepressant medication are associated with adherence and are potentially modifiable through improved patient-provider communication, psycho-education, and therapeutic interventions.
Copyright © 2013 John Wiley & Sons, Ltd.

Entities:  

Keywords:  antidepressant adherence; race/ethnicity; spirituality; stigma

Mesh:

Substances:

Year:  2013        PMID: 23801324     DOI: 10.1002/gps.3984

Source DB:  PubMed          Journal:  Int J Geriatr Psychiatry        ISSN: 0885-6230            Impact factor:   3.485


  10 in total

1.  Adherence to antidepressants among women and men described with trajectory models: a Swedish longitudinal study.

Authors:  Ann-Charlotte Mårdby; Linus Schiöler; Karolina Andersson Sundell; Pernilla Bjerkeli; Eva Lesén; Anna K Jönsson
Journal:  Eur J Clin Pharmacol       Date:  2016-08-03       Impact factor: 2.953

2.  Understanding racial-ethnic differences in patient-centered care (PCC) in oncology through a critical race theory lens: A qualitative comparison of PCC among Black, Hispanic, and White cancer patients.

Authors:  Kerri-Anne R Mitchell; Kelly J Brassil; Margaret L Osborne; Qian Lu; Richard F Brown
Journal:  Patient Educ Couns       Date:  2021-11-19

3.  Patient-provider communication, self-reported medication adherence, and race in a postmyocardial infarction population.

Authors:  Leah L Zullig; Ryan J Shaw; Bimal R Shah; Eric D Peterson; Jennifer H Lindquist; Matthew J Crowley; Steven C Grambow; Hayden B Bosworth
Journal:  Patient Prefer Adherence       Date:  2015-02-19       Impact factor: 2.711

4.  Validity and reliability of a novel Color-Risk Psychiatric Triage in a psychiatric emergency department.

Authors:  Alejandro Molina-López; Jeremy Bernardo Cruz-Islas; Mauricio Palma-Cortés; Diana Patricia Guizar-Sánchez; César Yehú Garfias-Rau; Martha Patricia Ontiveros-Uribe; Ana Fresán-Orellana
Journal:  BMC Psychiatry       Date:  2016-02-10       Impact factor: 3.630

5.  Extent and Factors Associated with Adherence to Antidepressant Treatment During Acute and Continuation Phase Depression Treatment Among Older Adults with Dementia and Major Depressive Disorder.

Authors:  Sandipan Bhattacharjee; Jeannie K Lee; Nina Vadiei; Asad E Patanwala; Daniel C Malone; Shannon M Knapp; Wei-Hsuan Lo-Ciganic; William J Burke
Journal:  Neuropsychiatr Dis Treat       Date:  2020-06-08       Impact factor: 2.570

6.  Protocol for studying racial/ethnic disparities in depression care using joint information from participant surveys and administrative claims databases: an observational cohort study.

Authors:  Macarius Donneyong; Charles Reynolds; David Mischoulon; Grace Chang; Heike Luttmann-Gibson; Vadim Bubes; McKenna Guilds; Joann Manson; Olivia Okereke
Journal:  BMJ Open       Date:  2020-01-07       Impact factor: 2.692

7.  Methylphenidate augmentation of escitalopram to enhance adherence to antidepressant treatment: a pilot randomized controlled trial.

Authors:  Martin P Paulus; Rayus Kuplicki; Teresa A Victor; Hung-Wen Yeh; Sahib S Khalsa
Journal:  BMC Psychiatry       Date:  2021-11-19       Impact factor: 3.630

8.  An Active Inference Approach to Dissecting Reasons for Nonadherence to Antidepressants.

Authors:  Ryan Smith; Sahib S Khalsa; Martin P Paulus
Journal:  Biol Psychiatry Cogn Neurosci Neuroimaging       Date:  2019-12-05

9.  Polybrominated Diphenyl Ether Serum Concentrations and Depressive Symptomatology in Pregnant African American Women.

Authors:  Abby D Mutic; Dana Boyd Barr; Vicki S Hertzberg; Patricia A Brennan; Anne L Dunlop; Linda A McCauley
Journal:  Int J Environ Res Public Health       Date:  2021-03-31       Impact factor: 3.390

10.  Baseline beliefs about medication are associated with outcomes of antidepressants in inpatients with first-diagnosed depression under supervised therapeutic compliance.

Authors:  Fan-Zhen Kong; Cai-Fang Ji; Xiang-Dong Du; Robert Logan; Hui-Ying Zhao; Guan-Hui Wu; Yan-Song Liu; Zhen Tang; Mei-E Niu
Journal:  Aging (Albany NY)       Date:  2021-09-02       Impact factor: 5.682

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.